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Alteplase Used in a Child with an Acute Ischemic Stroke
Shah Nawaz Chaudhary DO, James Espinosa MD, Alan Lucerna DO, Adam Richards MD
Emergency Medicine Residency and Department of Emergency Medicine, Rowan University, SOM
Abstract:

Discussion:

Stroke, also known as cerebrovascular accident (CVA), is a neurological injury caused by
inadequate brain perfusion due to either ischemia or hemorrhage. There is an abundance of
literature on the management of ischemic strokes in adults and this has led to well defined
diagnostic and treatment guidelines. However, the management of pediatric ischemic strokes is
currently based on clinical experience of experts, recommendations of consensus guidelines,
case studies and extrapolation from adult clinical trials. In this case report a pediatric patient
suffering from an ischemic stroke is successfully treated with IV alteplase (tPA).

Pediatric strokes are a relatively rare (1 to 2.5 per 100,000 children in the United States per year)
compared to adult strokes (up to 970 per 100,000 adults between ages 65 and 74 in the Unities States
per year) (1). While strokes in adults are commonly linked to risk factors such as hypertension,
hyperlipidemia, and diabetes, pediatric stroke risk factors include congenital heart disease, sickle cell
disease and leukemia (2). The patient in this case study had a history of HLHS, a ductal dependent
malformation that is universally fatal if not surgically palliated shortly after birth. Our patient had a
three-stage procedure that included the Norwood, Glen, and Fontan surgeries, which have been shown
to increase survival to 90% at 18 years of age. Unfortunately, despite improved mortality post-fontan,
almost all patients experience complications including thromboembolic events.

Introduction:
Stoke or cerebrovascular accident (CVA) is a neurological injury to the brain caused by either
ischemic or hemorrhagic insult. When a CVA is caused by ischemia and the patient has
debilitating neurological deficits, thrombolytics such as tPA is recommended as long as the
patient does not have any absolute contraindications. However, one of the primary indications
to administer tPA is age > 18 years old. If a child is suffering an ischemic stroke, tPA use would be
off-label and treatment should be coordinated with pediatric sub-specialists. Management is
based on clinical experience of experts, recommendations of consensus guidelines, case studies
and extrapolation from adult clinical trials.

Case Presentation:
A 15-year-old male was brought to the ED for difficulty speaking, left sided facial droop and left
sided weakness. Last known normal was approximately 30 minutes prior to arrival. The patient
had a past medical history of hypoplastic left heart syndrome (HLHS) surgically palliated via
“fontan surgery on day 3, 6 months and 18 months of life”. The patient’s medications included 81
milligrams aspirin every other day. Vital signs on arrival were a blood pressure of 119/62, heart
rate of 84 beats per minute, respiratory rate of 20 breaths per minute, oxygen saturation of 93%
on room air and oral temperature of 98.1F. The patient weighed 59.8 kilograms.

Figure 1: CT Head without IV contrast showing the focal hyperdensity circled in
red is known as the “hyperdense MCA sign”.

The current FDA approval of tPA in adult patients with strokes is supported by the NINDS rt-PA trial and
ECASS III trials. Although it is reasonable to consider tPA in children based on these studies, such
treatment is off-label extrapolation. The fibrinolytic system is a dynamic process that continues to
develop following birth and there are qualitative and quantitative differences in plasminogen and
plasminogen activator inhibitors in infants, children, and adults (4). These differences could affect
optimal tPA dosing in children. A major complication of administering tPA is bleeding, including
symptomatic intracranial hemorrhage (sICH) which increases morbidity and mortality. The rate of
symptomatic intracranial hemorrhage was 6.4% in the NINDS trial and 2.4% ECASS III trial (5) (6). Of
note, patients with ischemic stroke are at increased risk of spontaneous intracranial hemorrhage even
without use of thrombolytics (6). Therefore, administering tPA in acute strokes is a balance between
maximizing clot breakdown to enhance neurological recovery while minimizing risk of bleeding. The
patient in this case study received an adult dose of tPA, did not suffer any adverse outcome and had
improved neurological function, illustrating that there is a role of tPA in pediatric strokes, but optimal
dosing is still unknown.

On exam the patient was resting comfortably and in no acute distress. He was able to talk but
had moderate dysarthria. He was awake, alert and oriented to person, place and time. He had a
left upper and lower facial droop. He was unable to move his entire left upper extremity, 0/5 in
strength. His left lower extremity was weak, 3/5 in strength. The patient’s NIH Stroke Scale was
10 for left sided facial palsy, left upper extremity paralysis, left lower extremity weakness, and
dysarthria. Remainder of his exam was unremarkable.
Our patient underwent prompt neuro-imaging after establishing vascular access and
documenting a blood glucose of 68. CAT scan of his head without contrast showed concern for
hyperdense thrombus in the M1 segment of the right middle cerebral artery (MCA) [Figure 1]
and the CT angiogram of the head and neck confirmed complete occlusion of mid to distal M1
segment of right MCA with an intraluminal thrombus, which spanned approximately 8mm [Figure
2, 3].
These results were discussed with the on-call neurologist and neurosurgeon at a local tertiary
pediatric center who recommended administration of tPA and immediate transfer to their
hospital. tPA was administered (.9 mg/kg/dose, 10% bolus over one minute as bolus and
remainder over one hour as an infusion). When he arrived at the receiving hospital, a repeat
neurological exam showed the patient regained 3/5 strength in his left upper extremity but still
had a facial droop, dysarthria and left lower extremity weakness. The patient underwent a
mechanical thrombectomy where the clot was successfully removed from the right MCA with a
penumbra suction catheter. Post-suction angiography showed satisfactory flow in the right MCA.
The patient was admitted to the ICU where his neurological exam significantly improved during
his hospital stay. He regained 5/5 strength in all extremities and his dysarthria resolved but a
mild left lower facial droop was still slightly visible when he smiled. The patient had a negative
hypercoagulable workup. Bilateral upper and lower extremity venous ultrasounds were negative
for deep vein thromboses. Transthoracic echocardiogram and cardiac MRI showed normal postfontan anatomy and physiology without signs of intracardiac thrombi or vegetations. The patient
was started on anticoagulation (Lovenox). The patient had no incidence of bleeding or
symptomatic intracranial hemorrhage (sICH). The patient remained stable and by hospital day six
was discharged.

As the medical community continues to create and provide innovative treatment modalities to patients
with illnesses that have historically had poor prognostic outcomes, such as complex congenital heart
anomalies, the Emergency Department is faced with new and rare pathologies that can require rapid
diagnosis and treatment, including ischemic strokes in children. This changing landscape presents
challenges. One study showed clinicians diagnosing stroke in a pediatric patient as late as 3 months later
(3) and another study showed delay in brain imaging from symptom onset as late as 7.2 hours (4). The
patient discussed in this case study presented to a community hospital with adult comprehensive stroke
services but without pediatric subspecialty coverage. The clinicians in this case-study utilized their
knowledge of stroke care in adults and applied it to this pediatric patient. In less than 10 minutes an
emergency physician evaluated the patient, in less than 25 minutes the patient had CT scan of his head,
in less than 45 minutes the CT scan results was interpreted and in one hour and thirteen minutes of
arrival to the hospital (approximately one hour and 43 minutes from symptoms onset) the patient
received tPA. By the time the patient arrived to the receiving children’s hospital, he was able to move
his left upper extremity and had near complete neurological recovery after mechanical thrombectomy.

Conclusions:
Figure 2: CT Head with IV contrast showing complete occlusion of mid to distal
M1 segment of right MCA.

Pediatric strokes are relatively rare but result in death and lifelong disability if not appropriately
identified and treated. Emergency physicians are faced with the challenge to rapidly identify and care
for patients of any age presenting with strokes. Current treatment for pediatric strokes is based on
clinical expertise, case studies, and extrapolation from adult trials. The problem with using adult trials to
guide treatment in children is the fibrinolytic system in infants and children are different than that in
adults Without evidence-based dosing guidance, children remain at risk of unintended consequences
such as symptomatic intracranial hemorrhage and inadequate thrombolysis. The TIPS trial was the first
multicenter, dose-adaptive, prospective treatment trial in acute pediatric strokes but it unfortunately
lost funding due to lack of patient recruitment and other logistical issues (6). While another treatment
trial is needed to test tPA’s efficacy and risk, this case study adds the growing literature of thrombolysis
in pediatrics strokes.
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Figure 3: 3D reconstruction of the patients Circle of Willis which shows
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